Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Gelbenegger

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 20, 2026
Continuous versus intermittent infusion of high-dose meropenem in critically ill patients: an observational cohort studyFelix Bergmann, Marlene Prager, Katarina Kumpf, et al.
Thrombosis Journal|April 15, 2022
Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trialGeorg Gelbenegger, Juergen Grafeneder, Gloria M Gager, et al.
Cardiovascular Diabetology|May 20, 2024
Association of prediabetes with clinical outcomes in patients with chronic coronary syndrome: a post hoc analysis of the ISCHEMIA and ISCHEMIA-CKD trialsAnselm Jorda, Christian Hengstenberg, Irene M Lang, et al.
Scientific Reports|July 9, 2020
The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxinKatarina D Kovacevic, Nina Buchtele, Christian Schoergenhofer, et al.
Infection|June 16, 2023
Community-acquired and hospital-acquired bacterial co-infections in patients hospitalized with Covid-19 or influenza: a retrospective cohort studyAnselm Jorda, Cornelia Gabler, Amelie Blaschke, et al.
British Journal of Haematology|June 2, 2022
Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trialGeorg Gelbenegger, Ulrich Jaeger, Michael Fillitz, et al.
BMC Medicine|November 5, 2019
Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroupsGeorg Gelbenegger, Marek Postula, Ladislav Pecen, et al.
Frontiers in Cardiovascular Medicine|July 25, 2022
Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel DiseaseGloria M Gager, Ceren Eyileten, Marek Postula, et al.
Thrombosis and Haemostasis|June 5, 2018
Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human EndotoxemiaChristian Schoergenhofer, Michael Schwameis, Georg Gelbenegger, et al.
Scientific Reports|August 2, 2019
Defibrotide enhances fibrinolysis in human endotoxemia - a randomized, double blind, crossover trial in healthy volunteersChristian Schoergenhofer, Nina Buchtele, Georg Gelbenegger, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 20, 2026
Continuous versus intermittent infusion of high-dose meropenem in critically ill patients: an observational cohort studyFelix Bergmann, Marlene Prager, Katarina Kumpf, et al.
Thrombosis Journal|April 15, 2022
Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trialGeorg Gelbenegger, Juergen Grafeneder, Gloria M Gager, et al.
Cardiovascular Diabetology|May 20, 2024
Association of prediabetes with clinical outcomes in patients with chronic coronary syndrome: a post hoc analysis of the ISCHEMIA and ISCHEMIA-CKD trialsAnselm Jorda, Christian Hengstenberg, Irene M Lang, et al.
Scientific Reports|July 9, 2020
The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxinKatarina D Kovacevic, Nina Buchtele, Christian Schoergenhofer, et al.
Infection|June 16, 2023
Community-acquired and hospital-acquired bacterial co-infections in patients hospitalized with Covid-19 or influenza: a retrospective cohort studyAnselm Jorda, Cornelia Gabler, Amelie Blaschke, et al.
British Journal of Haematology|June 2, 2022
Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trialGeorg Gelbenegger, Ulrich Jaeger, Michael Fillitz, et al.
BMC Medicine|November 5, 2019
Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroupsGeorg Gelbenegger, Marek Postula, Ladislav Pecen, et al.
Frontiers in Cardiovascular Medicine|July 25, 2022
Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel DiseaseGloria M Gager, Ceren Eyileten, Marek Postula, et al.
Thrombosis and Haemostasis|June 5, 2018
Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human EndotoxemiaChristian Schoergenhofer, Michael Schwameis, Georg Gelbenegger, et al.
Scientific Reports|August 2, 2019
Defibrotide enhances fibrinolysis in human endotoxemia - a randomized, double blind, crossover trial in healthy volunteersChristian Schoergenhofer, Nina Buchtele, Georg Gelbenegger, et al.
Pageof 6